newsfilter
← Latest News
GlobeNewswire·

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized